Abstract
We read with great interest the multicenter and retrospective study of Fougerosse et al1 that investigated real-life effectiveness and tolerance of guselkumab at week 16 in the treatment of cutaneous psoriasis. In the same manner, we conducted the first multicenter study in Belgium aiming to investigate real-life effectiveness and tolerance of guselkumab at week 16 in the treatment of cutaneous psoriasis. Guselkumab is the first selective interleukin (IL)-23 p19 inhibitor (Tremfya®, Janssen Biotech, Inc., Horsham, PA, USA) marketed and reimbursed in Belgium.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the European Academy of Dermatology and Venereology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
